Research programme: CNS disorders therapeutics - NeuroTherapeutics Pharma
Alternative Names: NTP-2014Latest Information Update: 16 Jul 2016
At a glance
- Originator NeuroTherapeutics Pharma
- Class
- Mechanism of Action Symporter inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Epilepsy; Pain
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Epilepsy in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pain in USA
- 12 Nov 2009 Preclinical trials in Epilepsy in USA (unspecified route)